Efficacy and safety of glecaprevir/pibrentasvir as retreatment therapy for patients with genotype 2 chronic hepatitis C who failed prior sofosbuvir plus ribavirin regimen.
Atsunori KusakabeMasayuki KurosakiJun ItakuraKouji JokoTakehiro AkahaneKeiji TsujiHaruhiko KobashiTetsuro SohdaHiroyuki KimuraRyouichi NaritaKoichirou FurutaNamiki IzumiPublished in: Hepatology research : the official journal of the Japan Society of Hepatology (2019)
This study establishes the efficacy of GLE/PIB as retreatment in Japanese patients with GT2 chronic hepatitis C not responding to SOF + RBV.